-Blinatumomab (Blincyto) is a bispecific T-cell engager (BiTE) that targets CD19 and CD3, approved for the treatment of B-cell precursor ALL. Blinatumomab binds to CD19 on B cells and CD3 on T cells, facilitating the immune-mediated destruction of B cells. 147, 148 -Loncastuximab Tesirine (Zynlonta) is an antibody-drug conjugate targeting CD19, approved for relapsed or refractory large B-cell lymphoma. The monoclonal antibody component targets CD19, delivering a cytotoxic payload directly to the malignant B cells. In sentence co-occurrences: biomarkers and types of cancer Biomarkers play a critical role in immuno-oncology, aiding in the identification, characterization, and treatment of various cancers. In recent immuno-oncology publications, the cooccurrence of biomarkers with key cancer concepts highlights their importance in understanding TME, predicting treatment responses, and developing targeted therapies. The identification of biomarkers and their co-occurrence with cancer concepts enables personalized medicine approaches, tailoring treatments based on individual patient profiles and tumor characteristics.